Our next stock has a long history of market leadership, best-in-class products driven by consistent innovation, strong relationships with key industry intermediaries, and a good reputation among consumers/patients.
This time, I’ve identified a healthcare stock from Japan, which rarely trades at these low levels.
In the latest monthly review for ByteTree Venture, we cut the weakest links and update clients on recent corporate developments.
Quality stocks have lagged this bull market, and as a result, offer good value. Investors have been focusing on growth at seemingly any price, and that can never end well. In the long run, value is the only thing that rewards investors.
As the owner of the best and most diversified brand portfolio in the world, today’s company is the pinnacle of quality in many investors’ minds.
Switzerland’s pharmaceutical dominance is built on an ecosystem of self-reinforcing factors, creating a competitive advantage that is hard for other nations to replicate.
